secwatch.observer — SEC 8-K summary
======================================

Issuer:     SOLENO THERAPEUTICS INC (SLNO)
CIK:        0001484565
Form:       8-K
Filed at:   2026-05-18T13:06:24+00:00
Accession:  0001193125-26-228016
Event type: m_and_a
Sentiment:  neutral
Materiality: 1.00
Item codes: 1.02, 2.01, 3.01, 3.03, 5.01, 5.02, 5.03, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Soleno acquisition by Neurocrine Biosciences completed; all shares bought for $53.00 each
--------------------------------------------------------------------------------

- Tender offer expired May 15 with 88.9% of shares tendered; merger closed May 18, 2026.
- Stockholders received $53.00 per share in cash; total offer consideration funded via Neurocrine cash.
- All pre-merger directors and officers resigned; new directors and officers from Neurocrine appointed.
- Shares to be delisted from Nasdaq and deregistered with SEC; Form 15 to be filed.
- Loan agreement with Oxford Finance and 2014 ESPP terminated effective upon merger.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1484565/000119312526228016/0001193125-26-228016-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1484565/000119312526228016/d143266d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-228016

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer